R Xiang, Z Yu, Y Wang, L Wang, S Huo, Y Li… - … Pharmaceutica Sinica B, 2022 - Elsevier
The COVID-19 pandemic caused by the novel SARS-CoV-2 virus has caused havoc across the entire world. Even though several COVID-19 vaccines are currently in distribution …
TA Tummino, VV Rezelj, B Fischer, A Fischer… - Science, 2021 - science.org
Repurposing drugs as treatments for COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has drawn much attention. Beginning …
Molecular virology tools are critical for basic studies of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and for developing new therapeutics. Experimental …
B Meyer, J Chiaravalli, S Gellenoncourt… - Nature …, 2021 - nature.com
SARS-CoV-2 is the causative agent behind the COVID-19 pandemic, responsible for over 170 million infections, and over 3.7 million deaths worldwide. Efforts to test, treat and …
Unprecedented efforts of the researchers have been witnessed in the recent past towards the development of vaccine platforms for the control of the COVID-19 pandemic. Albeit …
Repurposing of currently available drugs is a valuable strategy to tackle the consequences of COVID-19. Recently, several studies have investigated the effect of psychoactive drugs on …
JK Stille, J Tjutrins, G Wang, FA Venegas… - European journal of …, 2022 - Elsevier
Severe diseases such as the ongoing COVID-19 pandemic, as well as the previous SARS and MERS outbreaks, are the result of coronavirus infections and have demonstrated the …
Since the beginning of the COVID-19 pandemic, large in silico screening studies and numerous in vitro studies have assessed the antiviral activity of various drugs on SARS-CoV …
JMO Rawson, A Duchon, OA Nikolaitchik, VK Pathak… - Viruses, 2021 - mdpi.com
The 3C-like protease (3CLpro) of SARS-CoV-2 is considered an excellent target for COVID- 19 antiviral drug development because it is essential for viral replication and has a cleavage …